Media headlines about SenesTech (NASDAQ:SNES) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. SenesTech earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.5623398403846 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several research analysts recently weighed in on SNES shares. Zacks Investment Research lowered shares of SenesTech from a “hold” rating to a “sell” rating in a research note on Friday, April 6th. Roth Capital reissued a “buy” rating on shares of SenesTech in a research report on Wednesday, April 4th. Finally, ValuEngine raised shares of SenesTech from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
SNES stock traded up $0.01 during midday trading on Friday, hitting $0.50. The company had a trading volume of 42,719 shares, compared to its average volume of 92,815. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.31 and a current ratio of 6.78. SenesTech has a 52 week low of $0.44 and a 52 week high of $8.20. The company has a market capitalization of $8.09, a P/E ratio of -0.44 and a beta of 0.81.
SenesTech (NASDAQ:SNES) last announced its quarterly earnings data on Thursday, March 29th. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. SenesTech had a negative return on equity of 194.40% and a negative net margin of 23,626.92%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.10 million. equities analysts predict that SenesTech will post -0.31 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://macondaily.com/2018/04/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-senestech-snes-share-price.html.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including plant-based fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.